UNITED STATES FOOD & DRUG ADMINISTRATION

Applications for FDA Approval to Market New Drug

OMB Control Number 0910-0014

Non-substantive Change Request:

I. Background:

This information collection supports FDA regulations in 21 CFR Part 312, which govern the use of investigational new drugs, including procedures and requirements for the submission of Form FDA 1571 entitled, "Investigational New Drug Application (IND)." Our primary objective in reviewing an IND is to help protect the rights and safety of subjects and to help ensure that the quality of the clinical trial is adequate to evaluate a drug's effectiveness and safety for the studied indication. To supplement the Form FDA 1571 instructions, we issued a draft guidance in May of 2015 entitled "Investigational New Drug Applications Prepared and Submitted by Sponsor Investigators" available at https://www.fda.gov/files/drugs/published/Investigational-New-Drug-Applications-Prepared-and-Submitted-by-Sponsor-Investigators.pdf. Form FDA 1571 is available as a fillable PDF document and accompanying instructions may be found on our website at https://www.fda.gov/media/116608/download.

II. Proposed change:

We have developed an additional collection method for data elements in Form FDA 1571 for research INDs (often/sometimes referred to as "non-commercial" INDs), however the scope of data being collected will remain unchanged. Also, the new collection method will only apply to research INDs. We generally consider a research IND to be one for which the sponsor (typically an individual investigator, academic institution or non-profit entity) does not intend to later commercialize the product. These studies are strictly for research, are usually shorter in duration than INDs for commercial development, and may result in publications in peer-reviewed journals. For sponsors (including sponsor/investigators) interested in filing or updating a research IND, a new web-based interface will be available on a mobile device or desktop to help sponsors fill out Form FDA 1571. The web-based interface will also allow sponsors to electronically submit the completed Form FDA 1571 and associated files.

The information being collected is described in 21 CFR 312.23 (a) through (f) and on Form FDA 1571, and will be submitted to FDA through a new, secure web-based interface. Use of this web-based submission is voluntary, and respondents may still elect to use a fillable PDF version of Form FDA 1571, submitted via mail, email, or fax. We believe the web-based collection method will enhance user experience with data submission to FDA and will help improve agency efficiencies. At the same time, we have made no adjustment to the currently estimated burden for the information collection at this time. Upon later evaluation we will modify our estimate as appropriate. Screenshots for the interface are included below.

Submitted: March 2021





APPLICATION BUILDER	Submit Research IND			
Application / Submission				
Company and Contact	Application/Submission Details			
O Product				
Nonclinical Studies				
Clinical Studies	Submission Type Find detailed information about the submission types on the FDA 1571 Instructions.	*This submission contains the following Initial	¥	
O Upload Documents	7	and a	,	
Review & Submit	IND Number	*IND Number		
	Provide the IND number if it was previously assigned. If an IND number has not been assigned, leave the field blank. For IND numbers less than six digits, the IND number	123456	Request IND Number	
	should be preceded using zeros (i.e., for IND 12345 enter 012345).			
	IND Serial Number	* IND Serial Number		
	IND submission should be consecutively numbered. The initial IND should be numbered Serial number: 0000: The next submission (e.g., amendment, report, or correspondence) should be numbered Serial Number: 0001: Subsequent submissions should be numbered consecutively in the order in which they are submitted.	0002		
	Select all that apply:	Emergency Research Exception From Informed Consent Requirements	i	
		Charge Request		
		Expanded Access Use 21 CFR 312.300		
		Please visit the Expanded Access page for more information about Individ		
		Individual Patient, Non-Emergency 21 CFR 312.310 Individual Patient, Emergency 21 CFR 312.310(d)	Intermediate Size Patient Population 21 CFR 312.315 Treatment IND or Protocol 21 CFR 312.320	
	Referenced Applications List Numbers of all Investigational New Drug Applications (21 CFR Part 312), New	Add Application +		
	Drug Applications (21 CFR Part 314), Drug Waster Files (21 CFR Part 314 A20), and Bloigifcs License Applications (21 CFR Part 601) referred to in this application.	Application Type Application Investigational New Drug Application 333333	on Number Letter of Authorization Authoritzation Letter 1.docx	0





APPLICATION BUILDER	Submit Research IND	
Application / Submission		
Company and Contact	Ann Francis (Cubardador Baballa	
Product	Application/Submission Details	
O Noncinical Studies		
Clinical Studies	Submission Type Find detailed information about the submission types on the FDA 15/1 instructions.	*This submission contains the following Protocol Amendment:
O Christiane	This consens internation access the each match types on the Lot 2.57.2 financiouns.	Protocol Americans
Upload Documents Fevire & Submit		*Type of Arrandment New Protocol (Nonclinical) New Protocol (Clinical) Change in Protocol (Nonclinical) Change in Protocol (Clinical) New Investigator New Human Factors Protocol Change in Human Factors Protocol
		MENANDA
	IND Number Provide the IND number if it was previously assigned. If an INO number has not been	*NO Number 121212
	assigned, leave the field blank. For IND numbers less than six digits, the IND number should be precised using zeros (i.e., for IND 12345 errier 012345).	
	IND Serial Number	*NO Serial Number
	IND submission should be consecutively numbered. The initial IND should be numbered Serial number: 0000: The nest submission (e.g., amendment, report, or correspondence) should be numbered Serial Number: 0001: Subsequent submissions should be numbered consecutively in the order in which they are submission.	0000
	Select all that apply:	Emergency Research Exception From Informed Consent Requirements
		Charge Request
		Expanded Access Use 21 CFR 312 300
		Rease visit the Expanded Access page for more information about Individual Ratients.
		Individual Patient, Non-Emergency 21 CFR 312:310 Individual Patient, Emergency 21 CFR 312:310(d) Treatment IND or Protocol 21 CFR 312:320
	Referenced Applications List Numbers of all Investigations New Drug Applications (21 CFR Part 312), New Drug Applications (21 CFR Part 314), Drug Marker Files (21 CFR Part 334-A20), and Biologies Ucanias Applications (21 CFR Part 501) referred to in this application.	Add Application +
	Previous	Save and Close Save No











A	PPLICATION BUILDER	Submit Research IND					
0	Application / Submission						
0	Company and Contact	Company and Contact Details					
0	Product						
0	Nonclinical Studies	Individual Details Enter details for the following Individuals	+ *Sponsor				
0	Clinical Studies		+ Sponsor Representative				
0	Upload Documents		+ Countersigner				
	Review & Submit	Person Responsible for Conduct					
		and Progress of Clinical Investigations	Salutation Select an Option ▼	*Title			
		Provide the Name and Title of the person responsible for monitoring the conduct and					
		progress of the clinical investigations (21 CFR 312.23(a)(1)(vi)). For Sponsor-Investigator	*First Name	Mlddle Name			
		INDs, the Investigator has this responsibility.					
			*Last Name				
			This is the same person as entered in the previous question				
		Person Responsible for Review					
		and Evaluation of Safety of the	Salutation	*Title			
		Drug Information Provide the Name and Title of the person	Select an Option ▼				
		responsible under 21 CFR 312.32 for review and evaluation of information relevant to the	*First Name	Mlddle Name			
		safety of the drug (21 CFR 312.23(a)(1))					
			*Last Name				
		Previous		Savi	re and Close	Save	Next


APPLICATION BUILDER	Submit Research IND
Application / Submission	
Company and Contact	Product Details
O Product	
Nonclinical Studies	Name of the Drug Name of Drug
O Clinical Studies	For name(s) of drug (21 CFR 312.23(a)(1)(i)), list the generic name(s) and trade name, if available. Also, provide the dosage form(s), and the unique ingredient identifier
Upload Documents	(UNII) term and code for active substances (If applicable). + Add Another Name
Review & Submit	Combination Product Information
	*(Proposed) Indication for Use Multiple Indications can be added in this section. Add Indication +
	Previous Save and Close Save Next





























APPLICATION BUILDER Submit Research IND Application / Submission Company and Contact **Upload Documents** O Product Upload contents of your IND Nonclinical Studies Document Type Clinical Studies O Upload Documents + Cover Letter 0 Review & Submit + Introductory Statement + General Investigational Plan + Chemistry, Manufacturing, and Control Data + Environmental Assessment or Claim for Exclusion + Nonclinical Literature Reference + Clinical Literature Reference + Additional Information



Previous



Save

Save and Close









AF	PPLICATION BUILDER	Submit Research IND						
0	Application / Submission							
0	Company and Contact	Upload Documents						
0	Product	1						
0	Nonclinical Studies	Upload contents of your IN	D					
0	Clinical Studies		Document Type					
0	Upload Documents	+	Cover Letter 0					
	Review & Submit	v	*Form FDA 1572 and Investigator CVs		Edit			
		+	Additional Information					
		Desidence				Country Class	Carra	Mout
		Previous				Save and Close	Save	Next



Nex	xt Page	Export			rt Data	Kes	et Form	ı
DEPARTMENT Foo	OF HEALTH od and Drug A			ICES		Expira	tion Date: N	DMB No. 0910-0014 March 31, 2022 ent on page 3.
INVESTIGATIONA (Title 21, Code of))	clinica	I investigation	ologic may be shipped or on begun until an IND for that effect (21 CFR 312.40)
. Name of Sponsor							2. Date of S	Submission (mm/dd/yyyy)
. Sponsor Address	(0.000 0.00 0.000 0.000						ephone Num	nber (Include country code if
Address 1 (Street address, P.O. b	ox, company n	name c/o)					modbie dila	area oode)
Address 2 (Apartment, suite, unit,	building, floor,	etc.)				6A. II	ND Number	(If previously assigned)
City		State/Province	ce/Region	1				,,,
Country		2	ZIP or Pos	stal Code		6B. S	elect One:	Commercial
Name of Drug (Include all available	le names: Trac	de, Generic, (Chemical,	, or Code)		\dashv		Research
					ontinuation age for #5			
A. (Proposed) Indication for Use		Is th	nis indicat	tion for a rare	e disease (p	orevalence	<200,000 in	U.S.)?
		Orp		oduct have a gnation for th			rovide the Or tion number n:	
B. SNOMED CT Indication Disease	Torm (Hoo oo	ntinuation no		[] 163		<u> </u>		
Phase of Clinical Investigation to I	be conducted New Drug App	Pha	se 1	Phase 2	☐ Phase 3	3 Oth	er (Specify):	
. Phase of Clinical Investigation to I . List numbers of all Investigational CFR Part 314.420), and Biologics 0. IND submission should be conse The next submission (e.g., amer	be conducted New Drug Apples License Appleecutively number and ment, report.	Pha	CFR Part	Phase 2 rt 312), New 601) referre	Phase 3 Drug Appli d to in this mbered "Se	3 Oth oth or other o	er (Specify): I CFR Part 3 i. er: 0000." per: 0001."	
. Phase of Clinical Investigation to I . List numbers of all Investigational CFR Part 314.420) , and Biologics 0. IND submission should be conse The next submission (e.g., amer Subsequent submissions should 1. This submission contains the foll Initial Investigational New Drug	be conducted New Drug App s License Appl ecutively numb dment, report be numbered owing (Select Application (IN	Pha plications (21 consecutive)	CFR Part CFR Part itial IND sindence) sily in the o	Phase 2 rt 312), New 601) referre	Phase 3 Drug Appli d to in this mbered "Se imbered "S h they are s	3 Oth octations (2' application octation octatio	er (Specify): I CFR Part (I. er: 0000." er: 0001."	314) , Drug Master Files (21
Phase of Clinical Investigation to I List numbers of all Investigational CFR Part 314.420), and Biologics Interpretation of the Interpretation of the Interpretation of Request For Reactivation of the Interpretation of Re	be conducted New Drug App s License Appl ecutively numb indment, report be numbered owing (Select Application (IN einstatement	Pha plications (21 consecutive)	CFR Part CFR Part titial IND s indence) s ly in the o Respon Annual	Phase 2 rt 312), New 601) referre chould be nu should be nu order in whice reserve to Clinical Report	Phase 3 Drug Appli d to in this mbered "Se imbered "S h they are s	3 Oth octations (2 application octations) octations (2 application octations) octations octation	er (Specify): I CFR Part (I. er: 0000." er: 0001."	Serial Number Request For Information
Phase of Clinical Investigation to I List numbers of all Investigational CFR Part 314.420), and Biologics Interpretation of the Interpretation of the Interpretation of Request For Reactivation Or Research of the Interpretation of Research of the Interpretation of Research of Interpretation o	be conducted New Drug App s License Appl ecutively numb indment, report, be numbered owing (Select Application (IN einstatement eport (DSUR)	Pha plications (21 (pered. The ini , or correspoi consecutive all that apply, ND)	CFR Part CFR Part titial IND s ndence) s y in the o) Respon Annual Other (s umendme	Phase 2 rt 312), New 601) referre should be nushould	Phase 3 Drug Applid to in this mbered "Sc imbered "S h they are s il Hold Request	3 Othications (2' application with application of the certain number erial Numbus submitted Response Generation of the certain number is application of the certain number is applicated number in the certain number in the certain number is applicated number in the certain number in the certain number is applicated number in the certain number in the certain number is applicated number in the certain number in the certain number in the certain number in the certain number is applicated number in the certain num	er (Specify): I CFR Part 3 I. er: 0000." er: 0001."	Serial Number Request For Information and and a safety Report
Phase of Clinical Investigation to I List numbers of all Investigational CFR Part 314.420) , and Biologics 0. IND submission should be conse The next submission (e.g., amer Subsequent submissions should 1. This submission contains the foll Initial Investigational New Drug Request For Reactivation Or Re Development Safety Update Re Protocol Amendment New Protocol PMR/P Protocol Change in Protocol	be conducted New Drug Apr s License Appl ecutively numb ndment, report be numbered owing (Select Application (IN einstatement eport (DSUR) In MC ol	Pha plications (21 (ications (CFR Part CFR Part CFR Part itial IND s indence) s yly in the o) Respon Annual Other (3 imendme Microbiolo logy/Toxic fety	Phase 2 rt 312), New 601) referre chould be nu should be nu order in which which see to Clinical Report Specify: ent ogy sology Statistics	Drug Applid to in this Drug Applid to in this mbered "Sc in they are s Il Hold Request Propri	3 Othications (2' applications (2' applications (2' applications) of the certain Numbus submitted Response Generations of the certain Numbus submitted	er (Specify): CFR Part 3 er: 0000." er: 0001." nse To FDA al Correspon Review Assessment	Serial Number Request For Information and and a serial Number IND Safety Report Initial Written Report Follow-up to a Written
. Phase of Clinical Investigation to I . List numbers of all Investigational CFR Part 314.420) , and Biologics 0. IND submission should be conse The next submission (e.g., amer Subsequent submissions should 1. This submission contains the foll Initial Investigational New Drug Request For Reactivation Or Re Development Safety Update Re Protocol Amendment New Protocol Change in Protocol New Investigator Human Protocol	be conducted New Drug App s License Appl ecutively numb ndment, report, be numbered owing (Select Application (IN einstatement eport (DSUR) In MC ol 1 Factors ol	Pha plications (21 (ications (CFR Part CFR Part ctital IND s indence) s indence	Phase 2 rt 312), New 601) referre chould be nu should be nu order in which which see to Clinical Report Specify: ent ogy sology Statistics	Phase 3 Drug Applid to in this mbered "St imbered "St	3 Oth ications (2' application erial numb erial Numb submitted Respo Gener for ng etary Nam al Protocol al Dispute F	er (Specify): CFR Part 3 er: 0000." er: 0001." nse To FDA al Correspon Review Assessment	Serial Number Request For Information and ance IND Safety Report Initial Written Report Follow-up to a Written Report
. Phase of Clinical Investigation to B List numbers of all Investigational CFR Part 314.420) , and Biologics 0. IND submission should be conse The next submission (e.g., amer Subsequent submissions should 1. This submission contains the following light of the content of the	be conducted New Drug Appl s License Appl ecutively numb indment, report, be numbered owing (Select Application (IN einstatement eport (DSUR) In MC Dol In Factors Dol In Factors Dol In Equation (IN	Pha plications (21 (21 (21 (21 (21 (21 (21 (21 (21 (21	CFR Part CFR Part CFR Part itial IND s indence) s by in the o color Respon Annual Other (s comendment Other (s) Comendment Type	Phase 2 rt 312), New 601) referre chould be nu should be nu order in which which see to Clinical Report Specify): ent ogy cology Statistics gy bination Proc (See instruction of the cology)	Phase 3 Drug Applid to in this mbered "Sc imbered "Sc	3 Oth ications (2' application erial numb erial Numb submitted Respo Gener for ng etary Nama al Protocol al Dispute F Requ (RFC	er (Specify): I CFR Part 3 Der: 0000." Per: 0001."	Serial Number Request For Information and and a company of the series o
. Phase of Clinical Investigation to I . List numbers of all Investigational CFR Part 314.420) , and Biologics 0. IND submission should be conse The next submission (e.g., amer Subsequent submissions should 1. This submission contains the folk Initial Investigational New Drug Request For Reactivation Or R Development Safety Update Re Protocol Amendment New Protocol Change in Protocol New Investigator Human Protocol Serio Originals, is the product a combination product (21 CFR 3.3) 3. Select the following only if applic Refer to the cited CFR section for	be conducted New Drug Appl s License Appl ecutively numb indment, report, li be numbered owing (Select Application (IN einstatement eport (DSUR) In MC Do I Factors Do I Fa	Pha plications (21 (idications (21 (id	CFR Part CFR Part CFR Part CFR Part itial IND s indence) s by in the o Annual Other (S indence) Come Type Int must be	Phase 2 Int 312), New 601) referred for the foliation of	Phase 3 Drug Applid d to in this mbered "Sc imbered "Sc imbered "S in they are s In Hold Request I Propri Specia Formal Juct tions) with applic Expand Jual Patient,	3 Oth ications (2' application (2' application (2' application erial Numb submitted Responsible Gener Gener Gener (RFC (RFC (RFC (RFC (RFC (RFC (RFC (RFC	er (Specify): I CFR Part 3 I. Incr: 0000." Incr: 0001." Inse To FDA Incr: 0001." Inse To FDA Incr: 0001." Inse To FDA Inse To	Serial Number Request For Information Indence IND Safety Report Initial Written Report Follow-up to a Written Report Report gnation ected below. R 312.300 rmediate Size Patient
. Phase of Clinical Investigation to It. List numbers of all Investigational CFR Part 314.420) , and Biologics 0. IND submission should be conset The next submission (e.g., amer Subsequent submissions should in the Initial Investigational New Drug Request For Reactivation Or Responsible Development Safety Update Responsible Protocol Amendment New Protocol PMR/P Change in Protocol Protocol New Investigator Human Protocol Service Ser	be conducted New Drug Appl s License Appl ecutively numb indment, report, l be numbered owing (Select Application (IN einstatement eport (DSUR) In MC ol Factors ol 2(e))? Ye eable. (Justifica or further inforr ottion From Infor	Pha plications (21 (idications (21 (id	CFR Part CFR Part CFR Part CFR Part itial IND s indence) s by in the o Annual Other (S indence) Come Type or must be	Phase 2 Int 312), New 601) referred 1010 re	Phase 3 Drug Applid to in this mbered "Sc imbered "S h they are s al Hold Request Propri Specia Formal duct tions) with applic Expand	3 Oth ications (2' application erial number and Numb submitted Responder and Protocol al Dispute Factor for all ded Access Non-R 312.310 Emergence	er (Specify): I CFR Part 3 I	Serial Number Request For Information and and a Written Report Follow-up to a Written Report gnation ected below. R 312.300
. Phase of Clinical Investigation to I . List numbers of all Investigational CFR Part 314.420) , and Biologics 0. IND submission should be conse The next submission (e.g., amer Subsequent submissions should 1. This submission contains the folk Initial Investigational New Drug Request For Reactivation Or Re Development Safety Update Re Protocol Amendment New Protocol New Investigator Human Protoco 2. For Originals, is the product a combination product (21 CFR 3.3 3. Select the following only if applic Refer to the cited CFR section for Emergency Research Excep Requirements, 21 CFR 312.3	be conducted New Drug Appl s License Appl ecutively numb indment, report, l be numbered owing (Select Application (IN einstatement eport (DSUR) In MC ol Factors ol 2(e))? Ye eable. (Justifica or further inforr ottion From Infor	Pha plications (21 (21 (21 (21 (21 (21 (21 (21 (21 (21	CFR Part CFR Part CFR Part Itial IND sindence) s ly in the o Marcology Content of the conte	Phase 2 Int 312), New 601) referred 1010 re	Phase 3 Drug Applid d to in this mbered "Se imbered "Secional Health and the second in t	3 Oth ications (2' application erial number and Numb submitted Responder and Protocol al Dispute Factor for all ded Access Non-R 312.310 Emergence	er (Specify): I CFR Part 3 I	Serial Number Request For Information and and and and and and and and and an
Development Safety Update Reprotocol Amendment New Protocol New Investigator Protocol New Investigation at 18 Select the following in the product a combination product (21 CFR 3.13.) Select the following only if applic Refer to the cited CFR section for Requirements, 21 CFR 3.12. Charge Request, 21 CFR 3.1	be conducted New Drug Appl s License Appl ecutively numb indment, report, l be numbered owing (Select Application (IN einstatement eport (DSUR) In MC ol Factors ol 2(e))? Ye eable. (Justifica or further inforr ottion From Infor	Pha plications (21 (21 (21 (21 (21 (21 (21 (21 (21 (21	CFR Part CFR Part CFR Part Itial IND sindence) s ly in the o CFR Part Itial IND sindence) s ly in the o Cother (sumendme (Microbiolology/Toxic fety armacolony) Cother (sumendme fety armacolony)	Phase 2 Int 312), New 601) referred 101 ref	Phase 3 Drug Applid d to in this mbered "Se imbered "Secional Health and the second in t	3 Oth ications (2' application erial number and Numb submitted Responding Gener for an an Protocol and Protocol and Dispute Form and Protocol and Company (RFL action for an added Access Non-R 312.310 Emergency)	er (Specify): I CFR Part 3 I	Serial Number Request For Information Indence IND Safety Report Initial Written Report Follow-up to a Written Report Report gnation ected below. R 312.300 rmediate Size Patient ulation, 21 CFR 312.315 atment IND or Protocol, JFR 312.320
8. Phase of Clinical Investigation to I 9. List numbers of all Investigational CFR Part 314.420) , and Biologics 10. IND submission should be conse The next submission (e.g., amer Subsequent submissions should 11. This submission contains the folk Initial Investigational New Drug Request For Reactivation Or Re Development Safety Update Re Protocol Amendment New Protocol New Investigator Human Protocol New Investigator Human Protocol 12. For Originals, is the product a combination product (21 CFR 3.3) 13. Select the following only if applic Refer to the cited CFR section for Emergency Research Excep Requirements, 21 CFR 312.3	be conducted New Drug Appl s License Appl ecutively numb indment, report, l be numbered owing (Select Application (IN einstatement eport (DSUR) In MC ol Factors ol 2(e))? Ye eable. (Justifica or further inforr ottion From Infor	Pha plications (21 (21 (21 (21 (21 (21 (21 (21 (21 (21	CFR Part CFR Part CFR Part Itial IND sindence) s ly in the o CFR Part Itial IND sindence) s ly in the o Cother (sumendme (Microbiolology/Toxic fety armacolony) Cother (sumendme fety armacolony)	Phase 2 Int 312), New 601) referred 101 ref	Phase 3 Drug Applid d to in this mbered "Se imbered "Secional Health and the second in t	3 Oth ications (2' application erial number application Respond Gener for all Protocol all Dispute F Requirements and P Requireme	er (Specify): I CFR Part 3 I	Serial Number Request For Information and and and and and and and and and an

	6. Protocol (21 CFR 312.23(a)(6)) a. Study protocol (21 CFR 312.23(a)	a)(6))		8. Pharmacology	and toxicology data (21 CFR 312.23(a)(8))
	4. General Investigational plan (21 CFR 3 5. Investigator's brochure (21 CFR 312.23			(21 CFR 312.	
	6. Protocol (21 CFR 312.23(a)(6))	- (-) (-))		(21 CFR 3	ental assessment or claim for exclusion 312.23(a)(7)(iv)(e))
	a. Study protocol (21 CFR 312.23(a	a)(6))			
	b. Investigator data (21 CFR 312.2	3(a)(6)(iii)(b)) or		an experience (21 CFR 312.23(a)(9))
	completed Form FDA 1572				formation (21 CFR 312.23(a)(10)) ser Fee Cover Sheet (Form FDA 3792)
	c. Facilities data (21 CFR 312.23(a Form FDA 1572)(6)(iii)(b)) or	r completed	=	ser Fee Cover Sheet (Form FDA 3792) s Certification of Compliance (Form FDA 3674)
15	. Is any part of the clinical study to be conducte	ed by a contr	act research	organization?	Yes No
	If Yes, will any sponsor obligations be transferr	ed to the cor	ntract researc	ch organization?	Yes
	If Yes, provide a statement containing the name identification of the clinical study, and a listing of				
16	. Name and Title of the person responsible for				<u> </u>
10	. Name and Title of the person responsible for	monitoring ti	ne conduct at	nd progress of the clinic	ai irrestigations
17	. Name and Title of the person responsible for	review and e	evaluation of	information relevant to	the safety of the drug
7	agree not to begin clinical investigation	e until 30	days after	EDA's receipt of the	IND unless I receive earlier notification
		agree not			
	y FDA that the studies may begin. I also	agree not	to begin or	r continue clinical in	vestigations covered by the IND if those
b					vestigations covered by the IND if those
b si	tudies are placed on clinical hold or fina	ıncial hold	. I agree tha	at an Institutional R	eview Board (IRB) that complies with the
b si	tudies are placed on clinical hold or fina equirements set forth in 21 CFR Part 56	ncial hold. will be res	. I agree tha sponsible f	at an Institutional Re or initial and contin	eview Board (IRB) that complies with the uing review and approval of each of the
b si re	tudies are placed on clinical hold or fina equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investiga	ncial hold. will be res	. I agree tha sponsible f	at an Institutional Re or initial and contin	eview Board (IRB) that complies with the
si re si	tudies are placed on clinical hold or fina equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investiga egulatory requirements.	ncial hold will be res ation. I agre	. I agree tha sponsible f ee to condi	at an Institutional Re or initial and contin	eview Board (IRB) that complies with the uing review and approval of each of the
si re si	tudies are placed on clinical hold or fina equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investiga	ncial hold will be res ation. I agre	. I agree tha sponsible f ee to condi	at an Institutional Re or initial and contin	eview Board (IRB) that complies with the uing review and approval of each of the
si re si re	tudies are placed on clinical hold or fina equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investiga egulatory requirements. Name of Sponsor or Sponsor's Authorized Re	uncial hold. will be resation. I agree	. I agree tha sponsible f ee to condi	at an Institutional Ro for initial and contin uct the investigation	eview Board (IRB) that complies with the uing review and approval of each of the n in accordance with all other applicable
si re si re	tudies are placed on clinical hold or fina equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investiga egulatory requirements.	uncial hold. will be resation. I agree	. I agree tha sponsible f ee to condi	at an Institutional Ro for initial and contin uct the investigation	eview Board (IRB) that complies with the uing review and approval of each of the n in accordance with all other applicable
si re si re	tudies are placed on clinical hold or fina equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investiga egulatory requirements. Name of Sponsor or Sponsor's Authorized Re	uncial hold. will be resation. I agree	. I agree tha sponsible f ee to condi	at an Institutional Ro for initial and contin uct the investigation	eview Board (IRB) that complies with the uing review and approval of each of the n in accordance with all other applicable when the country code if applicable and area code,
si re si re	tudies are placed on clinical hold or final equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investigate equilatory requirements. Name of Sponsor or Sponsor's Authorized Reference Number (Include country code if application). Address	nncial hold, will be res ation. I agre epresentative	. I agree tha sponsible f ee to condi	at an Institutional Ro for initial and contin uct the investigation	eview Board (IRB) that complies with the uing review and approval of each of the n in accordance with all other applicable
b: si re si re	tudies are placed on clinical hold or fina equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investiga egulatory requirements. Name of Sponsor or Sponsor's Authorized Re	nncial hold, will be res ation. I agre epresentative	. I agree tha sponsible f ee to condi	at an Institutional Ro for initial and contin uct the investigation	eview Board (IRB) that complies with the uing review and approval of each of the n in accordance with all other applicable when the country code if applicable and area code,
b: si re si re	tudies are placed on clinical hold or final equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investigate equilatory requirements. Name of Sponsor or Sponsor's Authorized Reference Number (Include country code if application). Address	nncial hold, will be resation. I agro	. I agree tha sponsible f ee to condi	at an Institutional Ro for initial and contin uct the investigation	eview Board (IRB) that complies with the uing review and approval of each of the n in accordance with all other applicable when the country code if applicable and area code)
si re si re	Address 2 (Apartment, suite, unit, building, floor	ancial hold, will be resation. I agroup the presentative dicable and ar name c/o)	. I agree tha sponsible fee to condu	at an Institutional Ro for initial and contin uct the investigation	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable when the country code if applicable and area code) 22. Email Address
si re si re	tudies are placed on clinical hold or final equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investigate equiatory requirements. Name of Sponsor or Sponsor's Authorized Research Telephone Number (Include country code if applications). Address Address 1 (Street address, P.O. box, company)	ancial hold, will be resation. I agroup the presentative dicable and ar name c/o)	. I agree tha sponsible f ee to condi	at an Institutional Ro for initial and contin uct the investigation	eview Board (IRB) that complies with the uing review and approval of each of the n in accordance with all other applicable when the country code if applicable and area code)
si re si re	Address 2 (Apartment, suite, unit, building, floor	ancial hold, will be resation. I agroup the presentative dicable and ar name c/o)	. I agree tha sponsible fee to condu	at an Institutional Refor initial and continuct the investigation	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable when the country code if applicable and area code, 22. Email Address
18 19	tudies are placed on clinical hold or final equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investigate equilatory requirements. Name of Sponsor or Sponsor's Authorized Research and the country code if application. Address Address 1 (Street address, P.O. box, company Address 2 (Apartment, suite, unit, building, floority Country	ancial hold, will be resation. I agroup the presentative dicable and ar name c/o)	. I agree tha sponsible fee to condi	at an Institutional Refor initial and continuct the investigation	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable when the country code if applicable and area code) 22. Email Address
by s1 re s1 18	Address Address 2 (Apartment, suite, unit, building, floo. City City City	ancial hold, will be resation. I agroup the presentative dicable and ar name c/o)	. I agree tha sponsible fee to condi	at an Institutional Refor initial and continuct the investigation	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable when the country code if applicable and area code) 22. Email Address
18 19 21	tudies are placed on clinical hold or final equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investigate equilatory requirements. Name of Sponsor or Sponsor's Authorized Research and the country code if application. Address Address 1 (Street address, P.O. box, company Address 2 (Apartment, suite, unit, building, floority Country	ancial hold, will be resation. I agroup the presentative dicable and ar name c/o)	. I agree tha sponsible fee to condi	at an Institutional Refor initial and continuct the investigation	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable when the country code if applicable and area code) 22. Email Address
by st re st re 18	tudies are placed on clinical hold or final equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investigate equilatory requirements. Name of Sponsor or Sponsor's Authorized Research and the country code if application. Address Address 1 (Street address, P.O. box, company Address 2 (Apartment, suite, unit, building, flooricity Country Name of Countersigner	nncial hold, will be resultion. I agree epresentative epresentative epresentative epresentative end are end are end are end end end end end end end end end en	. I agree tha sponsible fee to condi	at an Institutional Refor initial and continuct the investigation	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable above (Include country code if applicable and area code) 22. Email Address 23. Date of Sponsor's Signature (mm/dd/yyyy)
by st re st re 18	tudies are placed on clinical hold or final equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investigate equilatory requirements. Name of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and Sponsor or Sponsor or Sponsor's Authorized Research and Sponsor or Sponsor or Sponsor's Authorized Research and Sponsor or Spo	nncial hold, will be resultion. I agramative epresentative	. I agree tha sponsible fee to condi	at an Institutional Refor initial and continuct the investigation	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable above (Include country code if applicable and area code) 22. Email Address 23. Date of Sponsor's Signature (mm/dd/yyyy)
by st re st re 18	tudies are placed on clinical hold or final equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investigate equilatory requirements. Name of Sponsor or Sponsor's Authorized Research and the second of the s	nncial hold, will be resultion. I agramative epresentative	. I agree tha sponsible fee to condi	at an Institutional Refor initial and continuct the investigation	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable above (Include country code if applicable and area code) 22. Email Address 23. Date of Sponsor's Signature (mm/dd/yyyy)
by st re st re 18	tudies are placed on clinical hold or final equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investigate gulatory requirements. Name of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and Sponsor or Sponsor or Sponsor's Authorized Research and Sponsor or Spons	nncial hold, will be res ation. I agra epresentative iname c/o) r, etc.) State/Provi	ince/Region	at an Institutional Refor initial and continuct the investigation	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable and area code) 22. Email Address 23. Date of Sponsor's Signature (mm/dd/yyyy),
by st re st re 18	tudies are placed on clinical hold or final equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investigate equilatory requirements. Name of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and Sponsor or Sponsor or Sponsor's Authorized Research and Sponsor or Sponsor or Sponsor's Authorized Research and Sponsor or Spo	nncial hold, will be res ation. I agra epresentative iname c/o) r, etc.) State/Provi	. I agree tha sponsible fee to condi	at an Institutional Refor initial and continuct the investigation	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable other (Include country code if applicable and area code) 22. Email Address 23. Date of Sponsor's Signature (mm/dd/yyyy, 26. Email Address) WARNING: A willfully false statement
by st re st re 18	Address 1 (Street address, P.O. box, company City Country Name of Countersigner Address 1 (Street address, P.O. box, company Address 2 (Apartment, suite, unit, building, floor Address 1 (Street address, P.O. box, company City Country Address 2 (Apartment, suite, unit, building, floor Address 3 (Street address, P.O. box, company Address 4 (Apartment, suite, unit, building, floor City Country Address 5 (Countersigner Address 6 (Street address, P.O. box, company Address 7 (Street address, P.O. box, company Address 8 (Apartment, suite, unit, building, floor City City City Country Address 6 (Countersigner Address 7 (Street address, P.O. box, company Address 8 (Apartment, suite, unit, building, floor City	nncial hold, will be res ation. I agra epresentative iname c/o) r, etc.) State/Provi	ince/Region	at an Institutional Refor initial and continuct the investigation D. Facsimile (FAX) Nun al Code	eview Board (IRB) that complies with the using review and approval of each of the in accordance with all other applicable and area code) 22. Email Address 23. Date of Sponsor's Signature (mm/dd/yyyy, 26. Email Address WARNING: A willfully false statement is a criminal offense (U.S.C. Title 18,
by st re st re 18	Address 1 (Street address, P.O. box, company City Country Name of Countersigner Address 1 (Street address, P.O. box, company Address 2 (Apartment, suite, unit, building, flood Address 1 (Street address, P.O. box, company City Country Address 2 (Apartment, suite, unit, building, flood City Country Address 1 (Street address, P.O. box, company Address 2 (Apartment, suite, unit, building, flood City Country Address 1 (Street address, P.O. box, company Address 2 (Apartment, suite, unit, building, flood City Country City Country Country	nncial hold, will be res ation. I agra epresentative iname c/o) r, etc.) State/Provi	ince/Region	at an Institutional Refor initial and continuct the investigation D. Facsimile (FAX) Nun al Code	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable and area code) 22. Email Address 23. Date of Sponsor's Signature (mm/dd/yyyy, 26. Email Address
by st rest rest rest rest rest rest rest r	Address 1 (Street address, P.O. box, company City Country Name of Countersigner Address 1 (Street address, P.O. box, company Address 2 (Apartment, suite, unit, building, floor Address 1 (Street address, P.O. box, company City Country Address 2 (Apartment, suite, unit, building, floor Address 3 (Street address, P.O. box, company Address 4 (Apartment, suite, unit, building, floor City Country Address 5 (Countersigner Address 6 (Street address, P.O. box, company Address 7 (Street address, P.O. box, company Address 8 (Apartment, suite, unit, building, floor City City City Country Address 6 (Countersigner Address 7 (Street address, P.O. box, company Address 8 (Apartment, suite, unit, building, floor City	nncial hold. will be resation. I agree epresentative epres	ince/Region ZIP or Posta	at an Institutional Refor initial and continuct the investigation D. Facsimile (FAX) Nun al Code	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable aber (Include country code if applicable and area code) 22. Email Address 23. Date of Sponsor's Signature (mm/dd/yyyy, 26. Email Address WARNING: A willfully false statement is a criminal offense (U.S.C. Title 18, Sec. 1001).
by si re si re re si 18	tudies are placed on clinical hold or final equirements set forth in 21 CFR Part 56 tudies in the proposed clinical investigate equilatory requirements. Name of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor's Authorized Research and the second of Sponsor or Sponsor or Sponsor's Authorized Research and the second of Sponsor or Spo	nncial hold. will be resation. I agree epresentative epres	ince/Region ZIP or Posta	at an Institutional Refor initial and continuct the investigation D. Facsimile (FAX) Nun al Code	eview Board (IRB) that complies with the using review and approval of each of the n in accordance with all other applicable aber (Include country code if applicable and area code) 22. Email Address 23. Date of Sponsor's Signature (mm/dd/yyyy, 26. Email Address WARNING: A willfully false statement is a criminal offense (U.S.C. Title 18, Sec. 1001).

The information below applies only to requirements of the Paperw	vork Reduction Act of 1995.
The burden time for this collection of information is estimated to average 100 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden to the address to the right:	Department of Health and Human Services Food and Drug Administration Office of Operations Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."	Please do NOT send your completed form to this PRA Staff email address.
ORM FDA 1571 (03/19)- PREVIOUS EDITION OBSOLETE Page 3 of 3	